Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of fulvestrant dose regimens in ER-positive advanced breast cancer
2005-004247-54Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fulvestrant in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Jan 2006; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004247-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004247-54.